Relay Therapeutics (RLAY)

• Market cap: $529M
• 1 day: -4.91%
• 5 days: 4.38%
• 1 month: 18.32%
• 3 months: -30.80%
• 6 months: -47.46%
• Year to date: -27.91%
• 1 year: -52.96%
• 5 years: -91.16%
• 10 years: -91.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Employees: 261

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

441% more call options, than puts

Call options by funds: $606K | Put options by funds: $112K

149% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 35

22% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 36

20% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 6 (+1) [Q4]

3% more funds holding

Funds holding: 193 [Q3] → 199 (+6) [Q4]

1.02% more ownership

Funds ownership: 96.95% [Q3] → 97.96% (+1.02%) [Q4]

39% less capital invested

Capital invested by funds: $1.11B [Q3] → $676M (-$439M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 29% upside
• Avg. target: $15.25 392% upside
• High target: $23 642% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Wells Fargo	29% upside $4	Equal-Weight Initiated	17 Apr 2025
HC Wainwright & Co. Robert Burns 24% 1-year accuracy 41 / 173 met price target	416% upside $16	Buy Reiterated	7 Mar 2025
Goldman Sachs Salveen Richter 21% 1-year accuracy 4 / 19 met price target	481% upside $18	Buy Maintained	27 Feb 2025
Stifel Bradley Canino 11% 1-year accuracy 3 / 27 met price target	642% upside $23	Buy Maintained	27 Feb 2025